1 Min Read
Feb 28 (Reuters) - Atyr Pharma Inc
* Atyr Pharma Receives U.S. FDA orphan drug designation for the treatment of limb girdle muscular dystrophy with Resolaris™ Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.